This advisory introduces readers to digital therapeutics (DTx) and the benefits of their use in behavioral health. It describes the research, regulatory, and reimbursement implications for DTx as well as selection and implementation considerations.

This advisory introduces readers to Cannabidiol (CBD), how it is derived, how it differs from THC and other cannabinoids, the risks and harms of CBD use, and common misconceptions given its broad availability.

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.

The EAP Prescription Drug Toolkit and Fact Sheets provide guidance related to counseling, referrals, and follow-up services (e.g., alternatives to prescription drugs, workplace drug misuse and relapse prevention, dangers of combined drug use, screenings, and evaluations before returning to work).

Consejos para adolescentes: la realidad sobre la marihuana

This fact sheet for teens provides facts about marijuana. It describes short- and long-term effects, lists signs of use, and helps dispel common myths. It also can be used by prevention professionals, educators, health care providers, and others who come in contact with teens on a regular basis.

This guide supports health care providers, systems, and communities seeking to prevent marijuana use by pregnant women. It describes relevant research findings, examines emerging and best practices, identifies knowledge gaps and implementation challenges, and offers useful resources.

This report presents 2016 national estimates of use of alcohol, tobacco products, illicit drugs (such as, marijuana, cocaine, heroin, hallucinogens, and inhalants, as well as the misuse of opioids, prescription pain relievers, tranquilizers, stimulants, and sedatives), substance use disorders, and substance use treatment among people 12 years of age and older. It Includes national estimates of any mental illness, serious mental illness, major depressive episode, use of mental health services and suicidal ideation among adults ages 18 or older and national estimates of major depressive episode, use of mental health services among adolescents aged 12 to 17. Trend information on these topics are also presented.